New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
16:22 EDTLMCA, SIRI, GMCR, SBUX, ARO, ULTA, CELGOn The Fly: Closing Wrap
Stocks on Wall Street were lower following another session dominated by headlines concerning the geopolitical situation. Stocks were lower early in the session following the lower than expected University of Michigan consumer confidence reading. The market moved in a narrow range and crossed back and forth across the flat-line several times. Investors remain on edge following several recent poor economic reports out of China and frequent remainders of the upcoming elections in the Ukraine on Sunday. ECONOMIC EVENTS: In the U.S., producer prices fell 0.1% overall in February, versus an expected increase of 0.2%. The core reading, which excludes food and energy, fell 0.2%, versus an expected increase of 0.1%. The Reuters/University of Michigan Consumer Sentiment Survey for March unexpectedly dropped to a four-month low of 79.9. The preliminary reading for the month was expected by analysts to have come in at 81.8, which would have been a slight bump from the prior 81.6 figure. In Europe, citizens of the Crimea region of the Ukraine are likely to vote to secede this weekend, even as Ukraine, the U.S and the European Union maintain that the vote is illegal. U.S. Secretary of State John Kerry said he was told that Vladimir Putin is not prepared to make any decision regarding Ukraine until after the country's referendum. COMPANY NEWS: Liberty Media (LMCA) shares gained $9.11, or 7.22%, to $135.25 after the company announced last night that it plans to reclassify its common stock into two tracking stocks, one called Liberty Media Group and the other called Liberty Broadband Group. Liberty President & CEO Greg Maffei called the move "another step in Liberty’s process of offering investors greater choice, transparency and focus." Liberty said in conjunction with the plan that it would drop plans to buy the rest of Sirius XM (SIRI), in which it currently holds a 53% stake in. Sirius XM had previously suspended its stock repurchase program in connection with Liberty Media's proposal and it announced today that it now intends to resume the repurchase plan. Shares of Sirius advanced 7c, or 2.08%, to $3.44 following the news. MAJOR MOVERS: Among the notable gainers was beauty retailer Ulta Salon (ULTA), which advanced $5.75, or 6.42%, to $95.26 after the company’s fourth quarter results beat estimates. Also higher were shares of single-serve coffee machine maker Keurig Green Mountain (GMCR), which rose $7.09, or 6.68%, to $113.25 after the company agreed to new terms in its deal with coffee giant Starbucks (SBUX). Among the noteworthy losers was teen retailer Aeropostale (ARO), which dropped $1.47, or 20.14%, to $5.83 after its fourth quarter results and first quarter outlook missed analysts' consensus expectations and the company entered a financing deal with private equity firm Sycamore Partners. Also lower were shares of drug maker Celgene (CELG), which dropped $6.59, or 4.22%, to $149.41 after the U.K.'s healthcare guidance body issued new draft guidance on the use of the company's Revlimid drug. INDEXES: The Dow fell 43.22, or 0.27%, to 16,065.67, the Nasdaq dropped 15.02, or 0.35%, to 4,245.40, and the S&P 500 declined 5.21, or 0.28%, to 1,841.13.
News For LMCA;SIRI;GMCR;SBUX;ARO;ULTA;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 23, 2014
07:32 EDTCELGCelgene reports Q3 adjusted EPS 97c, consensus 95c
Subscribe for More Information
October 22, 2014
15:37 EDTCELGNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
11:55 EDTCELGStocks with call strike movement; YHOO CELG
Yahoo (YHOO) January 48 call option implied volatility decreased 6% to 32, Celgene (CELG) April 110 call option implied volatility increased 2% to 32 according to IVolatility.
11:38 EDTCELGBiogen retreats after Tecfidera sales miss, patient death reported
Subscribe for More Information
11:01 EDTCELGBiogen trading lower on slower growth, PML case, says Deutsche Bank
Deutsche Bank attributes the pullback in shares of Biogen (BIIB) to slower sequential revenue growth and the one PML case with Tecfidera disclosed on today's earnings call. Deutsche believes investors are now favoring Celgene (CELG) over Biogen due to near term headline risks. The firm says it likes Celgene more as well due its pipeline, but keeps a Buy rating on Biogen.
October 21, 2014
09:23 EDTCELGCelgene GED-0301 said to have 67% 12-week remission at high dose in trial
Subscribe for More Information
October 20, 2014
13:26 EDTCELGCelgene I&I franchise boosted by Crohn’s trial data, says William Blair
William Blair said it views the preliminary Phase II efficacy and safety data from mongersen in Crohn’s disease reported by Celgene as encouraging. The firm noted that the 10 mg arm did not achieve significance, but the three data points collectively formed a robust dose-response that William Blair said lends support for the drug's proposed mechanism of action. William Blair believes mongersen complements Celgene’s Inflammation & Immunology portfolio and the firm maintains its Outperform rating on the stock, which is up 4% to $91.65 in afternoon trading.
13:21 EDTCELGCelgene reports Phase II data in Crohn’s Disease to be presented at UEG
Subscribe for More Information
October 17, 2014
13:18 EDTCELGLeerink's biotech analyst holds an analyst/industry conference call
Subscribe for More Information
10:43 EDTAROUrban Outfitters slumps after warning on continued retail sales weakness
Subscribe for More Information
08:03 EDTGMCRKeurig receives notification from SEC regarding closing inquiry
Keurig Green Mountain announced it has received notification from the Securities and Exchange Commission that it is closing the previously disclosed four-year inquiry into accounting and disclosure matters at the company and would not be recommending any enforcement action against the company or any of its current or former employees.
October 16, 2014
15:11 EDTSBUXStarbucks confirms plans to roll out mobile ordering in U.S. in 2015
Subscribe for More Information
15:10 EDTCELGAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
08:06 EDTSBUXAlmunia says political pressure around Google case 'unprecented,' WSJ reports
Subscribe for More Information
05:50 EDTSIRIStocks with implied volatility movement; SHPG SIRI
Subscribe for More Information
October 15, 2014
07:55 EDTSBUXStarbucks checks refute bear case, says Bernstein
Subscribe for More Information
06:14 EDTGMCRKeurig Green Mountain implied volatility of 40 at lower end of index mean range
Subscribe for More Information
October 14, 2014
10:27 EDTULTAUlta Salon volatility elevated into investor meeting
Ulta Salon October call option implied volatility is at 47, November is at 33, December is at 42; compared to its 26-week average of 34 according to Track Data, suggesting large near term price movement into an Investor meeting on October 15.
October 13, 2014
11:53 EDTULTAUlta Salon to host investor meeting
Investor meeting to be held in Chicago on October 15 at 11 am. Webcast Link
07:26 EDTGMCRAB InBev has studied potential deal to acquire PepsiCo, Bloomberg says
Anheuser-Busch InBev (BUD), which has a history of growth via acquisition and has been speculated to be targeting peer SABMiller (SBMRY), has also studied whether a merger with PepsiCo (PEP) makes sense, according to Bloomberg, citing people familiar with the matter. The report added that one source said no talks between Anheuser-Busch and Pepsi are ongoing, no deal is imminent, and the scenario is among many that has been examined. The report also noted that Albert Fried views Monster Beverage (MNST) and Keurig Green Mountain (GMCR) as other suitable targets for AB InBev. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use